Benzinga | Jan 18, 2022 06:44AM EST

RBC Capital Downgrades Neurocrine Biosciences to Sector Perform, Lowers Price Target to $90

RBC Capital analyst Brian Abrahams downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Outperform to Sector Perform and lowers the price target from $122 to $90.